Log In
Print
BCIQ
Print
Print this Print this
 

Aryplase, Naglazyme, galsulfase

Also known as: Arylsulfatase B, rhASB

  Manage Alerts
Collapse Summary General Information
Company BioMarin Pharmaceutical Inc.
DescriptionRecombinant human N-acetylgalactosamine-4-sulfatase
Molecular Target Not available
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis VI (MPS VI)
Regulatory Designation

Partner

AnGes MG Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$81.0M

$81.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today